Johnson & Johnson Company Profile (NYSE:JNJ)

About Johnson & Johnson (JNJ)

Johnson & Johnson logoJohnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on over five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: JNJ
  • CUSIP: 47816010
Key Metrics:
  • Previous Close: $127.25
  • 50 Day Moving Average: $121.16
  • 200 Day Moving Average: $117.23
  • 52-Week Range: $2,713,346,000.00 - $107.69
  • Trailing P/E Ratio: 21.29
  • Foreward P/E Ratio: 17.11
  • P/E Growth: 3.06
  • Market Cap: $342.59B
  • Outstanding Shares: 2,713,346,000
  • Beta: 0.74
  • Net Margins: 22.78%
  • Return on Equity: 25.61%
  • Return on Assets: 13.40%
  • Debt-to-Equity Ratio: 0.32%
  • Current Ratio: 2.73%
  • Quick Ratio: 2.36%

Analyst Ratings

Consensus Ratings for Johnson & Johnson (NYSE:JNJ) (?)
Ratings Breakdown: 1 Sell Rating, 11 Hold Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.28)
Consensus Price Target: $123.79 (1.96% downside)

Analysts' Ratings History for Johnson & Johnson (NYSE:JNJ)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/11/2017Jefferies Group LLCReiterated RatingHold$125.00 -> $132.00N/AView Rating Details
1/26/2017Wells Fargo & CoDowngradeOutperform -> Market Perform$112.28 -> $112.80N/AView Rating Details
1/25/2017Royal Bank of CanadaLower Price TargetOutperform$133.00 -> $128.00N/AView Rating Details
1/25/2017Goldman Sachs Group IncLower Price TargetNeutral$120.00 -> $115.00N/AView Rating Details
12/20/2016Credit Suisse Group AGReiterated RatingHoldN/AView Rating Details
11/29/2016Barclays PLCDowngradeOverweight -> Equal Weight$130.00 -> $125.00N/AView Rating Details
11/28/2016Bank of America CorpReiterated RatingHold$126.00N/AView Rating Details
10/23/2016Societe GeneraleReiterated RatingHold$116.00N/AView Rating Details
10/21/2016ArgusReiterated RatingBuy$145.00N/AView Rating Details
9/11/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
9/7/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
8/19/2016Deutsche Bank AGReiterated RatingBuy$142.00N/AView Rating Details
7/20/2016BMO Capital MarketsReiterated RatingOutperform$132.00N/AView Rating Details
5/20/2016Raymond James Financial, Inc.Reiterated RatingOutperform$120.00N/AView Rating Details
5/20/2016Standpoint ResearchInitiated CoverageSell$94.00N/AView Rating Details
5/19/2016Morgan StanleyReiterated RatingHoldN/AView Rating Details
4/20/2016Piper Jaffray CompaniesBoost Price TargetNeutral$105.00 -> $106.00N/AView Rating Details
4/17/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
1/27/2016Independent Research GmbHSet Price TargetNeutral$108.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$95.00N/AView Rating Details
10/15/2015S&P Equity ResearchReiterated RatingBuy$120.00N/AView Rating Details
8/25/2015Cowen and CompanyReiterated RatingOutperform$114.00N/AView Rating Details
(Data available from 3/23/2015 forward)


Earnings History for Johnson & Johnson (NYSE:JNJ)
Earnings by Quarter for Johnson & Johnson (NYSE:JNJ)
Earnings History by Quarter for Johnson & Johnson (NYSE:JNJ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/24/2017Q416$1.56$1.58$18.28 billion$18.10 billionViewN/AView Earnings Details
10/18/2016Q316$1.66$1.68$17.71 billion$17.80 billionViewListenView Earnings Details
7/19/2016Q216$1.68$1.74$17.98 billion$18.50 billionViewListenView Earnings Details
4/19/2016Q116$1.65$1.68$17.50 billion$17.50 billionViewListenView Earnings Details
1/26/2016Q415$1.42$1.44$17.88 billion$17.80 billionViewListenView Earnings Details
10/13/2015Q315$1.45$1.49$17.47 billion$17.10 billionViewListenView Earnings Details
7/14/2015Q215$1.69$1.71$17.76 billion$17.80 billionViewListenView Earnings Details
4/14/2015Q115$1.54$1.56$17.40 billionViewListenView Earnings Details
1/20/2015Q414$1.26$1.27$18.59 billion$18.30 billionViewListenView Earnings Details
10/14/2014Q314$1.43$1.50$18.41 billion$18.50 billionViewListenView Earnings Details
7/15/2014Q214$1.54$1.66$18.86 billion$19.50 billionViewN/AView Earnings Details
4/15/2014Q114$1.48$1.54$18.00 billion$18.10 billionViewN/AView Earnings Details
1/21/2014Q413$1.20$1.24$17.95 billion$18.40 billionViewN/AView Earnings Details
10/15/2013Q313$1.32$1.36$17.46 billion$17.60 billionViewN/AView Earnings Details
7/16/2013Q2 2013$1.39$1.48$17.71 billion$17.90 billionViewN/AView Earnings Details
4/16/2013Q1 2013$1.41$1.44$17.46 billion$17.50 billionViewN/AView Earnings Details
1/22/2013Q4 2012$1.17$1.19$17.67 billion$17.60 billionViewN/AView Earnings Details
10/16/2012$1.21$1.25ViewN/AView Earnings Details
7/17/2012$1.29$1.30ViewN/AView Earnings Details
4/17/2012$1.34$1.37ViewN/AView Earnings Details
1/24/2012$1.09$1.13ViewN/AView Earnings Details
10/18/2011$1.21$1.24ViewN/AView Earnings Details
7/19/2011$1.24$1.28ViewN/AView Earnings Details
4/19/2011$1.26$1.35ViewN/AView Earnings Details
1/25/2011$1.03$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Johnson & Johnson (NYSE:JNJ)
Current Year EPS Consensus Estimate: $7.04 EPS
Next Year EPS Consensus Estimate: $7.38 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$1.60$1.67$1.64
Q2 20163$1.64$1.68$1.66
Q3 20162$1.63$1.71$1.67
Q4 20161$1.55$1.55$1.55
Q1 20171$1.71$1.71$1.71
Q2 20171$1.81$1.81$1.81
Q3 20171$1.75$1.75$1.75
Q4 20171$1.72$1.72$1.72
Q1 20181$1.86$1.86$1.86
Q2 20181$1.97$1.97$1.97
Q3 20181$1.91$1.91$1.91
(Data provided by Zacks Investment Research)


Current Dividend Information for Johnson & Johnson (NYSE:JNJ)
Most Recent Dividend:3/14/2017
Annual Dividend:$3.20
Dividend Yield:2.53%
Dividend Growth:6.70% (3 Year Average)
Payout Ratio:54.42% (Trailing 12 Months of Earnings)
45.45% (Based on This Year's Estimates)
43.36% (Based on Next Year's Estimates)
Track Record:54 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Johnson & Johnson (NYSE:JNJ)

Dividend History by Quarter for Johnson & Johnson (NYSE:JNJ)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Johnson & Johnson (NYSE:JNJ)
Insider Ownership Percentage: 0.11%
Institutional Ownership Percentage: 65.30%
Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)
Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)
Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/15/2017Paulus StoffelsVPSell22,000$117.29$2,580,380.00View SEC Filing  
10/21/2016Charles PrinceDirectorBuy875$114.11$99,846.25View SEC Filing  
7/26/2016Dominic J CarusoVPSell41,146$125.01$5,143,661.46View SEC Filing  
7/22/2016Ronald A KapustaCAOSell2,935$125.01$366,904.35View SEC Filing  
6/7/2016Gary J PrudenVPSell9,735$116.03$1,129,552.05View SEC Filing  
6/7/2016Ronald A KapustaCAOSell3,000$115.79$347,370.00View SEC Filing  
5/10/2016Ronald A KapustaCAOSell3,957$114.77$454,144.89View SEC Filing  
2/17/2016Paulus StoffelsinsiderSell125,000$102.43$12,803,750.00View SEC Filing  
2/3/2016Peter FasoloVPSell151,385$104.12$15,762,206.20View SEC Filing  
10/23/2015Ronald A. KapustaCAOSell6,239$99.68$621,903.52View SEC Filing  
6/2/2015Charles PrinceDirectorBuy2,500$99.22$248,050.00View SEC Filing  
4/28/2015Paulus StoffelsInsiderSell187,250$100.73$18,861,692.50View SEC Filing  
9/10/2014James CullenDirectorSell2,446$104.12$254,677.52View SEC Filing  
5/5/2014Stephen CosgroveInsiderSell22,000$100.05$2,201,100.00View SEC Filing  
3/14/2014Peter FasoloVPSell6,824$93.15$635,655.60View SEC Filing  
8/14/2013Stephen CosgroveInsiderSell17,200$91.39$1,571,908.00View SEC Filing  
8/5/2013Michael UllmannVPSell16,140$93.68$1,511,995.20View SEC Filing  
7/25/2013Paulus StoffelsInsiderSell45,440$92.40$4,198,656.00View SEC Filing  
7/18/2013Dominic J CarusoCFOSell30,000$90.31$2,709,300.00View SEC Filing  
11/12/2012James CullenDirectorSell13,900$69.70$968,830.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Johnson & Johnson (NYSE:JNJ)
Latest Headlines for Johnson & Johnson (NYSE:JNJ)
News IconJohnson & Johnson (JNJ) Receives Consensus Rating of "Hold" from Brokerages (NYSE:JNJ) - March 23 at 11:08 AM logoJohnson & Johnson Innovation Launches Singapore QuickFire Challenge Competition in Collaboration with … (NYSE:JNJ) - March 23 at 4:19 AM logoAT&T and Johnson & Johnson Pull Ads From YouTube (NYSE:JNJ) - March 22 at 11:17 PM logoWord On Wall Street: Pharma Segment Key To Johnson & Johnson's 2017 Performance (NYSE:JNJ) - March 22 at 6:16 PM logoJohnson & Johnson Is Due for a Pullback (NYSE:JNJ) - March 22 at 6:16 PM logoJohnson & Johnson, and Be The... (NYSE:JNJ) - March 21 at 6:02 PM logo[$$] Funding Snapshot: Pulmocide Raises $30.4 Million Series B for Respiratory Drugs (NYSE:JNJ) - March 21 at 6:02 PM logoJohnson & Johnson to Host Investor Conference Call on First-Quarter Results (NYSE:JNJ) - March 21 at 6:02 PM logoJohnson & Johnson's CaringCrowd®, work by CI&T and R/GA, Takes Home SXSW Interactive Innovation Award (NYSE:JNJ) - March 21 at 12:13 PM logoSPR Therapeutics Appoints Michael P. Chuisano to Board of Directors (NYSE:JNJ) - March 21 at 10:23 AM logoThird Talcum Powder Lawsuit Verdict Stands, after Missouri Court Denies ... (NYSE:JNJ) - March 20 at 4:19 PM logoWill Apple Be the Next AAA-Rated Company? (NYSE:JNJ) - March 20 at 4:19 PM logoJohnson & Johnson Has Let Shareholders Down (NYSE:JNJ) - March 20 at 10:51 AM logoWorld does better if US and China do better: J&J CEO (NYSE:JNJ) - March 20 at 10:51 AM logoA Prescription Blood Thinner Beat Aspirin at Preventing Recurrence of Blood Clots, Study Finds (NYSE:JNJ) - March 20 at 10:51 AM logo3 Stocks That Pay You to Own Them (NYSE:JNJ) - March 20 at 10:51 AM logoJ&J CEO: US needs to focus on the long-term sustainability of health care (NYSE:JNJ) - March 20 at 12:03 AM logoCompanies Don’t Disrupt, People Do (NYSE:JNJ) - March 19 at 5:28 PM logoCompound Interest Is Real Modern-Day Alchemy (NYSE:JNJ) - March 19 at 5:28 PM logoBills sign 3 free agents, including CB Leonard Johnson (NYSE:JNJ) - March 18 at 9:47 AM logoCautious On Johnson & Johnson Due To A DCF Analysis (NYSE:JNJ) - March 18 at 9:47 AM logo10 Reasons Johnson & Johnson Could Be the World's Most Perfect Stock (NYSE:JNJ) - March 17 at 6:17 PM logoWith Tax Overhaul on Back Burner, Companies Embrace M&A Abroad (NYSE:JNJ) - March 17 at 8:41 AM logoThat Was Fast: Healthcare ETF Races To New Highs (NYSE:JNJ) - March 16 at 6:53 PM logoJohnson & Johnson’s Financial Guidance for 2017 (NYSE:JNJ) - March 15 at 6:22 PM logoJohnson & Johnson's (JNJ) Management Presents at Barclays Global Healthcare Conference 2017 (Transcript) (NYSE:JNJ) - March 15 at 3:16 AM logoJohnson & Johnson: Be Wary Of Short-Term Thinking (NYSE:JNJ) - March 14 at 5:14 PM logoJohnson & Johnson Names Winners of First Africa Innovation Challenge (NYSE:JNJ) - March 14 at 11:40 AM logoJohnson & Johnson’s Medical Devices Segment (NYSE:JNJ) - March 14 at 11:40 AM logoTwo-part Ebola vaccine offers long-lasting protection (NYSE:JNJ) - March 14 at 11:40 AM logoRisperdal Lawsuits Contribute to Johnson & Johnson's Growing Legal Costs, Bernstein Liebhard LLP Reports (NYSE:JNJ) - March 13 at 5:53 PM logoOne Put, One Call Option To Know About for Johnson & Johnson (NYSE:JNJ) - March 13 at 5:53 PM logoOrtho Clinical Diagnostics Announces Expansion Of Global Agreement With Astute Medical For NephroCheck Test (NYSE:JNJ) - March 13 at 5:53 PM logo9 Stocks in the CNBC IQ 100 Hit Highs (NYSE:JNJ) - March 13 at 5:53 PM logoJohnson & Johnson’s Revenue Trends (NYSE:JNJ) - March 13 at 10:44 AM logoWord On Wall Street: Pharma Segment Key To Johnson & Johnson Performance In 2017 (NYSE:JNJ) - March 12 at 10:13 AM logoJNJ To Face More Lawsuits This Year (JNJ) - Investopedia (NYSE:JNJ) - March 10 at 7:17 PM logoJNJ To Face More Lawsuits This Year (JNJ) (NYSE:JNJ) - March 10 at 7:17 PM logoThe Contrarian: Is JNJ Worth the Premium? (NYSE:JNJ) - March 10 at 1:47 AM logoThe Lawsuits Keep Coming for Johnson & Johnson (NYSE:JNJ) - March 9 at 8:46 PM logoUS STOCKS-Wall St ends up slightly; energy shares rebound (NYSE:JNJ) - March 9 at 8:46 PM logoGLOBAL MARKETS-Oil prices slump amid ample supply, gold falls (NYSE:JNJ) - March 9 at 8:46 PM logoAAA Credit Rating Stocks In Focus: Johnson & Johnson - Seeking Alpha (NYSE:JNJ) - March 9 at 3:44 PM logoJohnson & Johnson to Close UK Plant - (NYSE:JNJ) - March 9 at 3:44 PM logoUS STOCKS-Wall St slips as energy shares fall further; banks pare gains (NYSE:JNJ) - March 9 at 3:44 PM logoTurf maker under fire hires lawyer who investigated Brady (NYSE:JNJ) - March 8 at 6:50 PM logo1 Thing About Pfizer, Inc. Stock That You Might Be Overlooking (NYSE:JNJ) - March 8 at 6:50 PM logoJohnson & Johnson In The Garden Portfolio - Seeking Alpha (NYSE:JNJ) - March 8 at 3:51 AM logoJohnson & Johnson Wins Talcum Powder Lawsuit - Investopedia (NYSE:JNJ) - March 8 at 3:51 AM logoJohnson & Johnson Just Won One of Its Talc Powder Cancer Lawsuits (NYSE:JNJ) - March 7 at 10:50 PM


Frequently Asked Questions for Johnson & Johnson (NYSE:JNJ)

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson declared a quarterly dividend on Tuesday, January 3rd. Stockholders of record on Tuesday, February 28th will be paid a dividend of $0.80 per share on Tuesday, March 14th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 2.53%. The ex-dividend date of this dividend is Friday, February 24th.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) announced its quarterly earnings data on Tuesday, January, 24th. The company reported $1.58 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.56 by $0.02. The company had revenue of $18.10 billion for the quarter, compared to the consensus estimate of $18.28 billion. Johnson & Johnson had a return on equity of 25.61% and a net margin of 22.78%. The firm's revenue for the quarter was up 1.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.44 earnings per share.

When will Johnson & Johnson make its next earnings announcement?

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, April, 18th 2017.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson issued an update on its FY17 earnings guidance on Tuesday, January, 24th. The company provided earnings per share guidance of $6.93-7.08 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.12. The company issued revenue guidance of $74.1-74.8 billion, compared to the consensus revenue estimate of $75.13 billion.

Where is Johnson & Johnson's stock going? Where will Johnson & Johnson's stock price be in 2017?

18 brokerages have issued 1-year target prices for Johnson & Johnson's stock. Their forecasts range from $94.00 to $145.00. On average, they anticipate Johnson & Johnson's stock price to reach $123.79 in the next year.

What are analysts saying about Johnson & Johnson stock?

Here are some recent quotes from research analysts about Johnson & Johnson stock:

  • 1. According to Zacks Investment Research, "J&J’s Pharma segment is performing well despite challenges like generic competition for a few products, potential biosimilar competition and lower HCV revenues.  While Pfizer’s launch of biosimilar Remicade creates some uncertainty regarding the segment’s sales growth in 2017, we believe that the impact may be manageable. Contribution from new as well as core products, share buybacks and the restructuring initiative should help drive results. Estimates have remained mostly stable lately ahead of the Q4 earnings results. J&J has a positive record of earnings surprises in recent quarters. J&J's shares have surpassed that of large-cap pharma industry in 2016. However, headwinds persist in the form of generics and biosimilar competition and pricing pressure." (1/9/2017)
  • 2. Jefferies Group LLC analysts commented, "With biosimilars and generics expected to drag the next few years, we expect JNJ will continue look to M&A to augment growth. Whilst this should ultimately drive better growth, we believe that investors will not reward the shares for this initially." (1/5/2017)
  • 3. Morgan Stanley analysts commented, "We need more evidence of execution to raise our numbers, but in a more bullish scenario the Consumer margin opportunity and growth acceleration in both segments could be worth ~9% upside to our current 2020 EPS estimate, and represent ~13% upside to J&J’s SOTP given the higher consumer multiple." (5/19/2016)

Who owns Johnson & Johnson stock?

Johnson & Johnson's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (5.64%), FMR LLC (1.21%), Norges Bank (1.03%), Barrow Hanley Mewhinney & Strauss LLC (0.44%), Franklin Resources Inc. (0.28%) and Dimensional Fund Advisors LP (0.24%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso, Gary J Pruden, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta.

Who sold Johnson & Johnson stock? Who is selling Johnson & Johnson stock?

Johnson & Johnson's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Aberdeen Asset Management PLC UK, Federated Investors Inc. PA, Numeric Investors LLC, Tweedy Browne Co. LLC, I.G. Investment Management LTD., TCW Group Inc. and Barrow Hanley Mewhinney & Strauss LLC. Company insiders that have sold Johnson & Johnson stock in the last year include Dominic J Caruso, Gary J Pruden, Paulus Stoffels and Ronald A Kapusta.

Who bought Johnson & Johnson stock? Who is buying Johnson & Johnson stock?

Johnson & Johnson's stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, State Street Corp, Russell Investments Group Ltd., Asset Management One Co. Ltd., DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, Renaissance Technologies LLC, Elkfork Partners LLC and Equity Investment Corp Acquisition Inc.

How do I buy Johnson & Johnson stock?

Shares of Johnson & Johnson can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Johnson & Johnson stock cost?

One share of Johnson & Johnson stock can currently be purchased for approximately $126.26.

Johnson & Johnson (JNJ) Chart for Thursday, March, 23, 2017

This page was last updated on 3/23/2017 by Staff